First Light Asset Management LLC Has Decreased Nektar Therapeutics (NKTR) Stake as Stock Value Declined

August 9, 2018 - By Vernon Prom

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment increased to 1.43 in 2018 Q1. Its up 0.24, from 1.19 in 2017Q4. It is positive, as 23 investors sold NKTR shares while 97 reduced holdings. 99 funds opened positions while 73 raised stakes. 153.40 million shares or 2.02% more from 150.36 million shares in 2017Q4 were reported. Parkside National Bank & Tru reported 0% stake. Fmr Limited Co holds 24.10M shares or 0.3% of its portfolio. State Street Corp has invested 0.06% in Nektar Therapeutics (NASDAQ:NKTR). Shell Asset Mngmt reported 20,261 shares. Jennison Ltd Company owns 0.04% invested in Nektar Therapeutics (NASDAQ:NKTR) for 384,978 shares. Signaturefd Limited Liability Corporation owns 0% invested in Nektar Therapeutics (NASDAQ:NKTR) for 3 shares. Arizona State Retirement System holds 0.04% or 39,900 shares in its portfolio. Raymond James And Assocs has 92,148 shares. 2,543 were accumulated by Raymond James Service Advsr. The Switzerland-based Credit Suisse Ag has invested 0.04% in Nektar Therapeutics (NASDAQ:NKTR). Covington owns 90 shares. Kepos Lp stated it has 12,348 shares. Japan-based Nomura Incorporated has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). Ameritas Prtn holds 0.08% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 16,122 shares. 1.28 million were reported by Morgan Stanley.

Since February 16, 2018, it had 1 buying transaction, and 33 insider sales for $89.16 million activity. Lingnau Lutz had sold 30,000 shares worth $3.05M on Thursday, April 5. The insider KUEBLER CHRISTOPHER A sold 40,000 shares worth $3.90M. $6.44M worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by ROBIN HOWARD W. 4,060 shares were sold by Hora Maninder, worth $338,563 on Wednesday, May 16. Another trade for 4,879 shares valued at $404,664 was sold by Nicholson John. $286,445 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Doberstein Stephen K.

First Light Asset Management Llc decreased its stake in Nektar Therapeutics (NKTR) by 14.69% based on its latest 2018Q1 regulatory filing with the SEC. First Light Asset Management Llc sold 51,655 shares as the company’s stock declined 11.70% with the market. The institutional investor held 300,086 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $31.89 million, down from 351,741 at the end of the previous reported quarter. First Light Asset Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $9.65 billion market cap company. The stock increased 0.57% or $0.32 during the last trading session, reaching $56.28. About 1.44 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 271.91% since August 9, 2017 and is uptrending. It has outperformed by 259.34% the S&P500.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: “Nektar Therapeutics’ (NKTR) CEO Howard Robin on Q2 2018 Results – Earnings Call Transcript” on August 09, 2018, also Seekingalpha.com with their article: “Rounds Report: Spark Therapeutics Ironically Topped Our Featured List Despite Its Depreciation” published on August 08, 2018, Seekingalpha.com published: “Rounds Report: Nektar Rallies Subsequent To An Overweight Rating By Piper Jaffray” on July 27, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Benzinga.com and their article: “Earnings Scheduled For August 8, 2018” published on August 08, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” with publication date: August 08, 2018.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 8 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Nektar Therapeutics had 12 analyst reports since March 29, 2018 according to SRatingsIntel. The stock has “Neutral” rating by H.C. Wainwright on Monday, June 11. As per Monday, June 4, the company rating was maintained by JP Morgan. H.C. Wainwright reinitiated the stock with “Buy” rating in Monday, April 2 report. The rating was maintained by PiperJaffray with “Overweight” on Friday, April 13. The firm has “Buy” rating given on Tuesday, June 5 by Canaccord Genuity. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Canaccord Genuity on Friday, May 11. The rating was maintained by Cowen & Co on Monday, June 4 with “Buy”. The firm earned “Buy” rating on Monday, April 9 by Cowen & Co. The rating was maintained by Mizuho with “Buy” on Friday, April 6. The rating was maintained by Mizuho on Thursday, March 29 with “Buy”.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.